A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Completed · Phase 3 · Has a placebo group

Conditions studied: Hereditary Angioedema Types I and II

In brief

The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period and who are eligible will then enter the treatment phase which comprises two sequential treatment periods. In the treatment phase, subjects will be randomized to one of four arms consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment period and treatment with low- or higher-volume placebo in the other treatment period. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment.

Key facts

Study ID

NCT01912456

Run by

CSL Behring

People needed

90

Starts

2014-01-01

Expected to finish

2015-10-01

Last updated by the study team

2021-01-29

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Run-In Period Inclusion Criteria:
• Males or females aged 12 years or older.
• A clinical diagnosis of hereditary angioedema type I or II.
• Hereditary angioedema attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.
• For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of Screening: use of a stable regimen within 3 months of Screening, with no plans to change.
• Eligibility Criteria for Entering Treatment Period 1:
• Laboratory confirmation of type I or type II hereditary angioedema, including C1-esterase inhibitor functional activity less than 50% AND C4 antigen level below the laboratory reference range.
• No clinically significant abnormalities as assessed using laboratory parameters.
• During participation in the run-in period, subjects must have experienced hereditary angioedema attacks that required acute treatment, required medical attention, or caused significant functional impairment.

You may not qualify if…

• Run-In Period Exclusion Criteria:
• History of clinical significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.
• Incurable malignancies at screening.
• Any clinical condition that will interfere with the evaluation of C1-esterase inhibitor therapy.
• Clinically significant history of poor response to C1-esterase therapy for the management of hereditary angioedema.
• Receiving therapy prohibited by the protocol, including medications for hereditary angioedema prophylaxis.
• Female subjects who started taking or changed dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing products) within 3 months prior to the screening visit.

Where it is running

• Study Site — Birmingham, Alabama, United States
• Study Site — Scottsdale, Arizona, United States
• Study Site — Bell Gardens, California, United States
• Study Site — La Jolla, California, United States
• Study Site — Orange, California, United States
• Study Site — Walnut Creek, California, United States
• Study Site — Colorado Springs, Colorado, United States
• Study Site — Chevy Chase, Maryland, United States
• Study Site — Boston, Massachusetts, United States
• Study Site — Cincinnati, Ohio, United States
• Study Site — Columbus, Ohio, United States
• Study Site — Toledo, Ohio, United States
• Study Site — Tulsa, Oklahoma, United States
• Study Site — Lake Oswego, Oregon, United States
• Study Site — Hershey, Pennsylvania, United States
• Study Site — Dallas, Texas, United States
• Study Site — Richmond, Virginia, United States
• Study Site — Virginia Beach, Virginia, United States
• Study Site — Spokane, Washington, United States
• Study Site — Campbelltown, New South Wales, Australia
• Study Site — Hamilton, Ontario, Canada
• Study Site — Ottawa, Ontario, Canada
• Study Site — Toronto, Ontario, Canada
• Study Site — Québec, Canada
• Study Site — Hradec Králové, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.